CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 24 enrolled
Drug / intervention
Rintatolimod +2 moredrug
Likely dose
Rintatolimod 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03734692
NCT03734692Phase 2Active
CompareCT.gov

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Robert Edwards·interventional·Posted Nov 8, 2018·Updated Feb 12, 2026

In Brief

A Phase 2 clinical trial evaluating Rintatolimod, Pembrolizumab, and 1 other intervention for Ovarian Cancer Recurrent. Active but no longer recruiting, targeting 24 participants across 1 site.

Detailed Summary

This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with recurrent platinum-sensitive ovarian cancer (OC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer Recurrent
CountriesUnited States
CollaboratorsAIM ImmunoTech Inc., Merck Sharp & Dohme LLC

Timeline

Phase 2Active
201920202021202220232024202520262027
First PostedNov 8, 2018
Enrollment StartJan 28, 2019
Primary CompletionJul 1, 2024
Study CompletionJan 10, 2027
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 7.6 years ago

Interventions

Rintatolimoddrug

200 mg by IP administration over 1-2 hours

Pembrolizumabdrug

200 mg will be administered as a 30 minute IV infusion

Cisplatindrug

50mg/m\^2 solution